Switching from Ozempic to Obeda: What You Need to Know
✓ Free to download
Find guidance on switching from Ozempic to Obeda in India, covering dose equivalence, safety considerations, and what to expect during the transition.
Availability update (October 2026): Dr. Reddy's paused commercial supplies of its semaglutide injection in July 2026 after some batches were found out of specification because of an issue with the active ingredient. The company said there was no impact on patient safety, and it has since started selling two new semaglutide brands, Obeda Pro and Obeda Plus. Check current stock with your pharmacist, and do not change brand, pen or strength without your prescriber.
Obeda launched in India in March 2026 at a lower price than Ozempic, so many patients who have been on Ozempic are asking: should I switch?
If you are on Ozempic and it is working, the case for switching is mainly financial. Whether it suits you is a decision for your doctor. This guide explains what to discuss.
Important: Always consult your healthcare provider before making any changes to your medication. This article is for informational purposes only.
Why Patients Are Switching
Before March 2026, Novo Nordisk's Ozempic (launched in India in December 2025) was the main injectable semaglutide option, and prices were higher. After a price cut from 1 April 2026, Ozempic was reported at about Rs. 5,660-9,100 depending on strength, with the 0.25mg starting dose at Rs. 1,415 per week.
Dr. Reddy's launched Obeda in 2mg and 4mg pens, each giving at least 4 weekly doses, at Rs. 4,200 per month for both strengths (launch price, March 2026). The 4mg pen covers 1mg weekly doses. The saving depends on your dose and current prices, so compare current MRPs with your pharmacist.
Is It Clinically Safe to Switch?
It can be, with medical supervision.
Obeda and Ozempic both contain semaglutide, and both are approved in India for type 2 diabetes. Dr. Reddy's was the first Indian company to receive DCGI approval for generic semaglutide, and it reported that Obeda showed non-inferior blood sugar control and a similar safety profile to the innovator in a head-to-head Phase III study of 312 participants. Full results had not been published in a journal at launch.
The pens, concentrations and inactive ingredients are not identical, so your doctor should confirm the right pen and dose. If you use Ozempic for weight management, note that Obeda's launch approval was for type 2 diabetes.
How to Switch: A Step-by-Step Guide
Step 1: Discuss With Your Doctor
Before switching, inform your prescribing doctor. They will:
- Confirm your current Ozempic dose
- Prescribe the equivalent Obeda dose
- Note any considerations based on your specific health profile
Do not switch without telling your doctor. Even though the change is low-risk, your doctor should have an accurate record of your medications.
Step 2: Confirm Dose Equivalence
Obeda launched as 2mg and 4mg pre-filled pens, each giving at least four weekly doses. If your doctor keeps the same weekly dose, it would typically look like this:
| Current Ozempic Dose | Same Obeda Dose (if your doctor agrees) |
|---|---|
| 0.25mg weekly | 0.25mg weekly |
| 0.5mg weekly | 0.5mg weekly |
| 1mg weekly | 1mg weekly |
Ozempic launched in India in 0.25mg, 0.5mg and 1mg strengths, and Obeda's launch pens cover the same weekly doses. If you were prescribed a higher dose elsewhere, ask your doctor about options. The Obeda pen device is different from the Ozempic FlexTouch. Your pharmacist can walk you through the Obeda pen and the right pen strength for your dose.
Step 3: Take Your Last Ozempic Injection as Normal
Continue your normal weekly injection schedule. Your last Ozempic injection is your last injection in the old series.
Step 4: Begin Obeda on Your Next Scheduled Injection Day
On your normal next weekly injection day, use Obeda instead of Ozempic, unless your doctor gives you a different plan. Doctors commonly plan the switch this way so there is no gap and no overlap. Never take both in the same week.
Step 5: Monitor for the First 4 Weeks
In the first month after switching, pay attention to:
- Appetite suppression -- should remain consistent with what you were experiencing on Ozempic
- Side effects -- should not worsen meaningfully; if they do, report to your doctor
- Blood sugar -- if you check it at home, especially if you also take insulin or a sulfonylurea
- Injection experience -- the pen device is different; learn the Obeda technique
Get urgent medical help for severe stomach pain that does not go away (it may spread to your back, with or without vomiting), pain in the upper right abdomen with fever or yellowing of the skin or eyes, signs of a serious allergic reaction (swelling of the face, lips or throat, trouble breathing), or vomiting or diarrhoea so severe you cannot keep fluids down. If you also take insulin or a sulfonylurea, know the signs of low blood sugar, as your doses of those medicines may need adjusting. Tell your doctor about any vision changes if you have diabetic eye disease, and tell the team before any surgery or sedation. Semaglutide carries a US boxed warning about thyroid C-cell tumours and must not be used if you or a close relative has had medullary thyroid carcinoma (MTC) or if you have MEN 2. Do not use it if you are pregnant or planning a pregnancy without talking to your doctor first.
See the Obeda pen guide if you need a walkthrough of the new device.
What to Expect After Switching
For most people the transition is expected to be smooth, as the active ingredient and dose are the same.
Some people may notice:
- Slightly different tolerability in the early weeks, possibly linked to the different formulation or pen. Report any change to your doctor.
- Different injection experience from the pen device change.
- Uncertainty about a new brand -- this is understandable; talk it through with your doctor or pharmacist.
If you have any concerns after switching -- unexpected side effects, significantly changed appetite suppression, or anything unusual -- contact your doctor.
Common Questions From Patients Considering the Switch
"My doctor says to stay on Ozempic. What should I do?"
Follow your doctor's advice. They may have reasons specific to you, such as your dose, other medicines, how well your diabetes is controlled, or supply of a particular brand (Obeda injection supply was paused from July 2026).
It is reasonable to ask what the reasons are and whether a lower-cost option might suit you later, but do not switch brands without your prescriber's agreement.
"I have been getting great results on Ozempic. What if Obeda is not as good?"
Similar results would be expected, because the active ingredient, dose and mechanism are the same, and Dr. Reddy's reported non-inferior blood sugar control in its Phase III study. There are no long-term studies of people switching, so keep tracking your progress and share it with your doctor.
"Is there any reason NOT to switch?"
Reasons to stay on Ozempic can include: your doctor's clinical judgement about your case, a sensitivity to an ingredient in another formulation, needing a weekly dose above 1mg, using semaglutide for weight management rather than type 2 diabetes, or supply problems with a particular brand. Cost is an important factor, but it is one of several.
The Financial Case in Numbers
| Product | Reported price (dated) |
|---|---|
| Obeda (2mg or 4mg pen) | Rs. 4,200 per month for both strengths (launch price, March 2026) |
| Ozempic | About Rs. 5,660-9,100 depending on strength, after Novo Nordisk's April 2026 price cut |
These are dated company and media figures, not current offers. The real saving depends on your dose, pack and pharmacy, so check current MRPs before deciding with your doctor.
How Weight Easy Supports the Transition
Whether you are new to Obeda or switching from Ozempic, the dietary, coaching, and tracking support from Weight Easy works the same way. The molecule is the same; the journey continues.
If you are switching to Obeda, Weight Easy helps you log doses, side effects and weight so you and your doctor can see how the switch is going, regardless of which pen you are using.
The Bottom Line
Switching from Ozempic to Obeda can lower the cost of semaglutide treatment for type 2 diabetes, and the active ingredient is the same. Whether it suits you, which pen and dose you use, and when you switch are decisions for your doctor. Check current Obeda supply first, as Dr. Reddy's paused injection supplies from July 2026.
Consult your healthcare provider before making any changes to your medication.
Sources
- Dr. Reddy's Obeda injection launch release (21 March 2026): https://www.drreddys.com/cms/sites/default/files/2026-03/finalpressrelease-Dr.Reddy%27sSemalaunch-21stMarch2026.pdf
- Apollo Pharmacy listing, Obeda 1 mg (4 mg/3 ml) pen: https://www.apollopharmacy.in/medicine/obeda-1-mg-prefilled-pen-injection-1-s
- Dr. Reddy's delays commercial semaglutide supplies after an ingredient issue (Daily Excelsior/PTI, 9 July 2026): https://www.dailyexcelsior.com/dr-reddys-delays-anti-diabetic-semaglutide-commercial-supplies-after-issues-with-ingredient/
- Obeda injection supply pause and launch of Obeda Pro and Obeda Plus (India Weekly, October 2026): https://www.indiaweekly.biz/dr-reddys-launches-two-new-semaglutide-brands-after-obeda-injection-supply-disruption/
- Ozempic and Wegovy India price ranges after the April 2026 cut (Outlook Business, 31 March 2026): https://www.outlookbusiness.com/corporate/novo-nordisk-cuts-ozempic-wegovy-prices-by-up-to-48-amid-generic-pressure
- Novo Nordisk India Ozempic starting-dose price from 1 April 2026 (BioSpectrum India): https://biospectrumindia.com/news/16/27598/novo-nordisk-india-sets-patient-centred-price-of-rs-202-day-for-starting-dose-of-ozempic-and-wegovy.html
- Ozempic US prescribing information (Novo Nordisk, revised May 2026): https://www.novo-pi.com/ozempic.pdf
- Novo Nordisk launches Ozempic in India for type 2 diabetes (The Week/PTI, 12 December 2025): https://www.theweek.in/wire-updates/business/2025/12/12/dcm26-biz-novo-nordisk-diabetes.html
- Central Drugs Standard Control Organisation (CDSCO): https://cdsco.gov.in/opencms/opencms/en/Home/
FAQ
Can I switch from Ozempic to Obeda?
Possibly, if your doctor agrees. Both contain semaglutide and both are approved in India for type 2 diabetes. Your doctor decides whether a switch suits you, which pen and dose to use, and how to monitor you afterwards. Obeda injection supply was paused from July 2026, so check availability first.
Will I notice a difference switching from Ozempic to Obeda?
Most people would not expect a large difference, as the active ingredient is the same. Dr. Reddy's reported that Obeda was non-inferior to the innovator in a 312-person Phase III study. The pen and inactive ingredients differ, so tell your doctor about any change in side effects or blood sugar.
Do I need to restart at the lowest dose when switching to Obeda?
Not necessarily. If there is no gap in treatment, doctors often continue the same weekly dose, but this is your prescriber's decision. Obeda's launch pens cover doses up to 1 mg weekly, matching the Ozempic strengths launched in India (0.25, 0.5 and 1 mg).
How much money can I save by switching from Ozempic to Obeda?
At launch in March 2026, Dr. Reddy's priced Obeda at Rs. 4,200 per month for both its 2mg and 4mg pens. After Novo Nordisk's April 2026 price cut, Ozempic was reported at about Rs. 5,660-9,100. Prices change, so compare current MRPs for your prescribed dose with your pharmacist.
Is it safe to switch without a gap between Ozempic and Obeda?
Doctors commonly plan the first Obeda dose for the day the next Ozempic dose would be due, without a gap. Follow the timing and dose your doctor gives you, and never take both in the same week.
Will my weight loss results change after switching?
Results would be expected to be similar, since the active ingredient and dose are the same, but there are no long-term switching studies. Keep tracking your weight, blood sugar and side effects and share them with your doctor.
Written by
Dietician / Nutritionist
Health Content Writer
Kritika Singh is a Dietician / Nutritionist professional who contributes evidence-informed health and wellness content for Weight Easy.
View profile →Reviewed by
Ph. D in Food Science and Nutrition
Senior Medical Reviewer
Dr. Shunmukha Priya. S is a Ph. D in Food Science and Nutrition professional who reviews Weight Easy health content for medical and editorial accuracy.
View profile →